Morinda citrifolia is one of the most important traditional polynesian medicinal plant. This small evergreen tree is native of South Eastern Asia to Australia and now it has pantropical distribution all over the world. This plant has antifungal, antibacterial, anti-inflammatory and antiviral activities. The present study aqueous, methanol and ethanol extraction of leaf extract of Morinda citrifolia was carried out since this method is more suitable for clinical study. The leaf extract was prepared by conventional extraction method and it was assessed with minimum inhibitory concentration (MIC) method against clinical isolate of Pseudomonas aeruginosa. In the present study have found that ethanol extracts showed better antibacterial activity against P.aeruginosa when compared to methanol extract. Aqueous extract showed no activity against P.aeruginosa by MIC method. Solvent control also showed no activity against P.aeruginosa .The overall results indicates, methanol and ethanol extracts of  M.citrifolia ,some useful drugs may be develop for the treatment of infectious diseases caused by P.aeruginosa.. The results revealed that plant extracts have inhibitory activity against the tested organism.

Keywords: Morinda citrifolia, Antibacterial activity, Aqueous,Methanol, Ethanol leaf extract.

1. Abuqaddom, A.I., Darwish, R.M., & Muti H. (2003).The effects of some formulation factors used in ophthalmic preparations on thiomersal activity against Pseudomonas aeruginosa and Staphylococcus aureus.J Appl Microbiol. 95(2), 250-255.
2. Abd Aziz, S.M., Low, C.N., Abd Razak, S.S.N., Selamat, J., Son, R., Sarker, M.Z.I., & Khatib, A. (2011). Screening of selected Malaysian plants against several food borne pathogen bacteria. Food. Res. J. 18(3), 1195-1201.
3. Alan, R., & Hauser. (2009). The role of type III effector proteins in the pathogenesis of acute pneumonia. Nature Reviews Microbiology.7, 654-665.
4. Arancibia, F., Bauer, T.T., Ewig, S., Mensa, J., Gonzalez, J., Niederman, M.S., & Torres, A. (2002). Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 162, 1849-1858.
5. Arpornsuwan, T., & Punjanon, T. (2006) Tumor cell selective anti proliferative effect of the extract from Morinda citrifolia Phytother. 20, 515-517.
6. Anders, F., Lars, J., Lei, Y., Helle, K.J., Oana, C., Niels, H., & Soren, M. (2012). Defects in mucociliary clearance of the CF airway creates opportunities for microbial colonization. Nature Reviews Microbiology.10, 841-851.
7. Basri, D.F., & Fan, S.H. (2005). The potential of aqueous and acetone extracts of galls of Quercus infectoria as antibacterial agents. J. Pharmacol. 37(1), 26-29.
8. Brimer, C.D., & Montie, T.C. (1998).  Cloning and comparison of fliC genes and identification of glycosylation in the flagellin of Pseudomonas aeruginosaa type strains. J Bacteriol. 180, 3209–3217.
9. Carmeli, Y., Troillet, N., Eliopoulos, G.M., & Samore, M.H. (1999). Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.Antimicrob Agents Chemother. 43(6), 1379-82.
10. Carle Gessard, Bossard, E.,La, P.M., & Février. (1962). (1850-1925), 479-480.
11. Chang, W.N., Lu, C.H., Huang, C.R., & Chuang, Y.C. (2000).Mixed infection in adult bacterial meningitis. 28(1), 8-12.
12. Chen, S.P., & Selena. (2009). Pseudom-onas eMedicine Pediatrics: General Medicine.
13. Cheng, B.C., Chang, W.N., Lu, C.H., Chen, J.B., Chang, C.S., Lee, C.H., et al. (2004). Bacterial meningitis in hemodia-lyzed patients. J Nephrol. 17(2), 236-41.
14. Committee on Infectious Diseases. (2006). The use of systemic fluoroquinolones. Pediatrics. 118(3), 1287-92.
15. Conlon, J.M., Sonnvened, A., Patel, M., Daviuudson, C., Npelson, P.F., Pasl, T., & Smith, L. (2003). Isolation of peptides of the brevinin family with potent candicidal activity from the skin secretions of the frog Rana boylii. Journal of Peptide Research. 5, 207.
16. Cornelis, P. (2008). Pseudomonas: Genomics and Molecular Biology, 1st ed., Caister Academic Press. ISBN 978- 1-904455-19-6
17. Costerton, J. W., P. S. Stewart, & E. P. Greenberg.(1999). Bacterial biofilms: a common cause of persistent infections. Science. 284, 1318-1322.
18. Costerton, J.W., & Lappin-Scott, H.M.(1995). Introduction to microbial biofilms, 1-11.  Cambridge University Press, Cambridge, United Kingdom.
19. Ciofu, O. (2003). Pseudomonas aeruginosachromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection - mechanism of antibiotic resistance and target of the humoral immune response. 111, 4–47.
20. Craig, W., & Ebert, S. (1994). Antimirobial Therapy in Pseudomonas aeruginosa  Pseudomonas aeruginosa Infections and Treatment.  470-491.
21. Deretic, D. (2000). Rhodopsin trafficking in photoreceptors using retinal free system. mech enzymol. 315, 77-88.
22. Dogget, R.G. (1969). Incidence of mucoid aeruginosa from clinical sources. Aapl. Microbial. 18, 936-937.
23. O’Donnell, J., Zeppenfeld, D., McConnell, E., Pena, S., & Nedergaard, M. (2012). Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Res. 37, 2496–2512. doi: 10.1007/s11064-012-0818-x.
24. Doring,, Meisner, C., & Stern, M. (2007). A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. P Natl Acad Sci USA. 104, 11020–11025.
25. Esath, N., Sekar, C., Amutharaj, P., Syed Abdul Rahman, M., Feroz Khan, K. (2012). Evaluation of antibacterial activity of Morinda citrifolia, Vitex trifolia and Chromolaena odorata. Afr. J. Pharm. Pharmacol. 6(11), 783-788.
26. Engleberg, N.C., & Dermondy, T.S. (2007). Fourth ed: Lippincott Williams & Wilkins.
27. Engel, J., &  Eran, Y., (2011). Subversion of mucosal barrier polarity by Pseudomonas aeruginosa. Front Micro-biol. 2,10.3389/fmicb.2011.00114.
28. Enoch, D. A., Simpson, A. J., & Kibbler, C. C. (2004). Predictive value of isolating Pseudomonas aeruginosa from aerobic and anaerobic blood culture bottles.Journal of Medical Microbiology. 53 (11), 1151-1154.
29. Favero, M.S., Carson, L.A., Bond, W.W., & Petersen, N.J. (1971). Pseudomonas aeruginosa: growth in distilled water from hospitals. Science. 173(999), 836-8.
30. Feldman, M., Bryan, R., Rajan, S., Scheffler, L., Brunnert, S., Tang, H., & Prince, A. (1998). Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun. 66, 43-51.
31. Fick, R. (1993).Pseudomonas aeruginosa - the Microbial Hyena and Its Role in Disease: An Introduciton. Pseudomonas aeruginosa: The Opportunist.1-6.
32. Fleiszig, S.M., Zaidi, T.S., & Pier, G.B. (1995). Pseudomonas aeruginosainvasion of and multiplication within corneal epithelial cells in vitro. Infect Immun.63,4072-4077.
33. Fleiszig,M., Evans, D.J., Do, N., Vallas, V., Shin, S., & Mostov, K.E. (1997). Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity. Infect Immun. 65, 2861–2867.
34. Gerson, S., Palu, A.K., Zhou, B.N., Su, C., Jensen, C.J., Story, S.P., et al. (2006). Formulation for inhibiting fungal and microbial growth comparing Morinda citrifolia puree juice. United States patent 7048952.
35. Giamarellou, H., & Antoniadou, A. (2001). Antipseudomonal antibiotics.Med Clin North Am. 85(1), 19-42.
36. Giamarellou, H. (1992). Malignant otitis externa: the therapeutic evolution of a lethal infection.J Antimicrob Chemother. 30(6), 745-51.
37. Gottenbos, B., Van der Mei, H. C. & Busscher, H. J. (1999). Models for studying initial adhesion and surface growth in biofilm formation on surfaces. Methods Enzymol. 310, 523-534.

Dashwa Langbang

Department of Microbiology, Dr.AL Mudaliar Post Graduate Institute of Basic Medical Sciences,

University of Madras, Taramani, Chennai- 113, South India